A Nonrandomized, Open-label Study to Evaluate the Safety and Pharmacokinetics of Multiple Administration of RC28-E Injection (a Chimeric Decoy Receptor Trap Fusion Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Wet Age-Related Macular Degeneration
Latest Information Update: 12 Jan 2022
At a glance
- Drugs RC28 E (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors RemeGen
Most Recent Events
- 06 Jan 2022 Status changed from active, no longer recruiting to completed.
- 26 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 22 Apr 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.